EP Patent

EP3923943B1 — Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency

Assigned to Mirum Pharmaceuticals Inc · Expires 2024-07-31 · 2y expired

What this patent protects

Patent listed against maralixibat-chloride.

Drugs covered by this patent

maralixibat-chloride (MARALIXIBAT CHLORIDE)

Patent Metadata

Patent number: EP3923943B1
Jurisdiction: EP
Classification: —
Expires: 2024-07-31
Drug substance claim: No
Drug product claim: No
Assignee: Mirum Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.